研發產品概況

研發中新藥 Pipeline (SIF緩釋藥物輸送平臺)

Product / Indication Research Pre-clinical Phase I Phase II Phase III NDA/MAA Market
CAMCEVI (Leuprolide, FP-001)
Prostate Cancer, CAMCEVI 42 mg
Prostate Cancer, CAMCEVI 21 mg
Central Precocious Puberty
FP-014 (Triptorelin)
Prostate Cancer
FP-016 (Undisclosed)
Neurology/Psychiatry
FP-004 (Buprenorphine) — Immediately Available for Partnering
Opioid Dependence/Pain
FP-011 (Goserelin) — Immediately Available for Partnering
Breast Cancer

研發中新藥 Pipeline (NCE 合理性藥物設計)

Product / Indication Research Pre-clinical Phase I Phase II Phase III NDA/MAA Market
FP-025 (MMP-12 Inhibitor)
POC Phase 2 study in allergic asthma patients
Acute Exacerbations of COPD/ILD
FP-020 (MMP-12 Inhibitor)
Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema
FP-045 (ALDH2 Activator)
POC Phase 1b/2 study in Fanconi Anemia (Pediatric formulation)
Cardiovascular, Renal and Metabolism (CVRM) /Peripheral artery disease (PAD)
FP-040 (ALDH2 Activator)
Central Nervous System (CNS) Diseases